MADISON, N.J., Nov. 16 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth , has been recognized for its leading scientific and pharmaceutical achievements with the “Management Team of the Year” award at the second annual Scrip Awards ceremony held on November 15 in London. An independent review board of scientists and specialists chose the Wyeth Research and Development Executive Committee (RADEX) for this honor from among other industry leaders. Scrip World Pharmaceutical News is an international pharmaceutical and biotechnology business publication.
“This award reflects the superb talent, dedication and innovative work executed by Wyeth executives,” says Bernard Poussot, President and Vice Chairman, Wyeth. “In an industry based on, and guided by, those who work to improve the health of others, it is an honor to be recognized for succeeding in that mission.”
The Scrip Award for “Management Team of the Year” honors RADEX as a group that is “much more than the sum of its parts.” RADEX, which governs a research and development (R&D) organization of approximately 7,000 Wyeth R&D employees globally, developed and put into place a new R&D productivity model nearly six years to oversee the progression of numerous therapeutic entities along the research continuum, from discovery to the clinic into the marketplace.
Combined with Wyeth’s strength and breadth across three pharmaceutical platforms (small molecules, biopharmaceuticals and vaccines) and multiple therapeutic areas, the R&D productivity model is bearing fruit with two major New Drug Applications (NDAs) submitted in 2005 and four NDAs in 2006. Now Wyeth’s pipeline is balanced with a range of new molecular entities in development that will position the Company as a leader far into the future.
The recent rollout of a new “Learn and Confirm” paradigm for drug development exemplifies how RADEX is continually realigning and optimizing cross-functional teams for maximum results.
About Scrip
Established in 1972, Scrip World Pharmaceutical News is the leading source of global business news in the pharmaceutical and biotechnology industries. Scrip is published bi-weekly by PJB Publications and can be found at www.pjbpubs.com.
About Wyeth
Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women’s health care, cardiovascular disease, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products. Wyeth is one of the world’s largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company’s major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare, and Fort Dodge Animal Health.
The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include risks associated with the inherent uncertainty of the timing and success of product research, development and commercialization (including with respect to our pipeline products), drug pricing and payment for our products by government and third-party payors, manufacturing, data generated on the safety and efficacy of our products, economic conditions including interest and currency exchange rate fluctuations, changes in generally accepted accounting principles, the impact of competitive or generic products, trade buying patterns, global business operations, product liability and other types of litigation, the impact of legislation and regulatory compliance, intellectual property rights, strategic relationships with third parties, environmental liabilities, and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption “Item 1A, Risk Factors.” We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Wyeth
CONTACT: Media: Gerald Burr of Wyeth Pharmaceuticals, +1-484-865-5138, orDouglas Petkus of Wyeth, +1-973-660-5218; Investors: Justin Victoria ofWyeth, +1-973-660-5340
